Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
ZYDUS LIFESCIENCES MYLAN |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ZYDUS LIFESCIENCES Mar-23 |
MYLAN Dec-18 |
ZYDUS LIFESCIENCES/ MYLAN |
5-Yr Chart Click to enlarge
|
||
High | Rs | 495 | 3,945 | - | |
Low | Rs | 319 | 2,171 | - | |
Sales per share (Unadj.) | Rs | 170.3 | 1,815.3 | - | |
Earnings per share (Unadj.) | Rs | 19.8 | 49.3 | - | |
Cash flow per share (Unadj.) | Rs | 26.9 | 389.2 | - | |
Dividends per share (Unadj.) | Rs | 6.00 | 0 | - | |
Avg Dividend yield | % | 1.5 | 0 | - | |
Book value per share (Unadj.) | Rs | 173.0 | 1,963.8 | - | |
Shares outstanding (eoy) | m | 1,012.20 | 514.50 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 2.4 | 1.7 | 141.9% | |
Avg P/E ratio | x | 20.6 | 62.0 | 33.2% | |
P/CF ratio (eoy) | x | 15.1 | 7.9 | 192.5% | |
Price / Book Value ratio | x | 2.4 | 1.6 | 151.1% | |
Dividend payout | % | 30.3 | 0 | - | |
Avg Mkt Cap | Rs m | 412,144 | 1,573,481 | 26.2% | |
No. of employees | `000 | NA | 35.0 | 0.0% | |
Total wages/salary | Rs m | 24,564 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 26,685.0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 724.6 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 172,374 | 933,975 | 18.5% | |
Other income | Rs m | 4,746 | 0 | - | |
Total revenues | Rs m | 177,120 | 933,975 | 19.0% | |
Gross profit | Rs m | 29,677 | 241,678 | 12.3% | |
Depreciation | Rs m | 7,227 | 174,877 | 4.1% | |
Interest | Rs m | 1,299 | 44,921 | 2.9% | |
Profit before tax | Rs m | 25,897 | 21,880 | 118.4% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 5,878 | -3,481 | -168.9% | |
Profit after tax | Rs m | 20,019 | 25,361 | 78.9% | |
Gross profit margin | % | 17.2 | 25.9 | 66.5% | |
Effective tax rate | % | 22.7 | -15.9 | -142.7% | |
Net profit margin | % | 11.6 | 2.7 | 427.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 100,082 | 521,531 | 19.2% | |
Current liabilities | Rs m | 55,267 | 380,253 | 14.5% | |
Net working cap to sales | % | 26.0 | 15.1 | 171.9% | |
Current ratio | x | 1.8 | 1.4 | 132.0% | |
Inventory Days | Days | 50 | 84 | 60.2% | |
Debtors Days | Days | 94 | 93 | 100.2% | |
Net fixed assets | Rs m | 144,776 | 181,176 | 79.9% | |
Share capital | Rs m | 1,012 | 497 | 203.5% | |
Net worth | Rs m | 175,158 | 1,010,390 | 17.3% | |
Long term debt | Rs m | 0 | 1,090,535 | 0.0% | |
Total assets | Rs m | 244,940 | 2,710,259 | 9.0% | |
Interest coverage | x | 20.9 | 1.5 | 1,407.9% | |
Debt to equity ratio | x | 0 | 1.1 | 0.0% | |
Sales to assets ratio | x | 0.7 | 0.3 | 204.2% | |
Return on assets | % | 8.7 | 2.6 | 335.6% | |
Return on equity | % | 11.4 | 2.5 | 455.3% | |
Return on capital | % | 15.5 | 3.2 | 488.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 26,888 | 194,080 | 13.9% | |
From Investments | Rs m | 11,712 | -100,318 | -11.7% | |
From Financial Activity | Rs m | -44,004 | -90,414 | 48.7% | |
Net Cashflow | Rs m | -5,338 | 1,608 | -332.0% |
Compare ZYDUS LIFESCIENCES With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare ZYDUS LIFESCIENCES With: TRIDENT LIFELINE ISTREET NETWORK LINCOLN PHAR SANJIVANI PA ZENITH HEALTH
Asian shares slipped before a Bank of Japan policy decision where authorities are likely to bring an end to the world's last negative rates regime.